Literature DB >> 7680751

Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.

F J Monsma1, Y Shen, R P Ward, M W Hamblin, D R Sibley.   

Abstract

We have used the polymerase chain reaction technique to selectively amplify a guanine nucleotide-binding protein-coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned serotonin receptors. Sequencing of a full length clone isolated from a rat striatal cDNA library revealed an open reading frame of 1311 base pairs, encoding a 437-residue protein with seven hydrophobic regions. Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E. Northern blots revealed a approximately 4.2-kilobase transcript localized in various brain regions, with the following rank order of abundance: striatum >> olfactory tubercle > cerebral cortex > hippocampus. Expression of this clone in COS-7 cells resulted in the appearance of high affinity, saturable binding of (+)-[2-125I] iodolysergic acid diethylamide ([125I]LSD) with a Kd of 1.26 nM. Among endogenous biogenic amines, only 5-HT completely inhibited [125I]LSD binding (Ki = 150 nM). The inhibition of [125I]LSD binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described serotonin receptor subtype. In addition, this receptor exhibits high affinity for a number of tricyclic antipsychotic and antidepressant drugs, including clozapine, amoxipine, and amitriptyline. In HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of adenylyl cyclase activity, which is blocked by antipsychotic and antidepressant drugs. The distinct structural and pharmacological properties of this receptor site indicate that it represents a completely novel subtype of serotonin receptor. Based on its affinity for tricyclic psychotropic drugs and its localization to limbic and cortical regions of the brain, it is likely that this receptor may play a role in several neuropsychiatric disorders that involve serotonergic systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680751

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  93 in total

1.  Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors.

Authors:  E Glusa; H H Pertz
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.

Authors:  C Routledge; S M Bromidge; S F Moss; G W Price; W Hirst; H Newman; G Riley; T Gager; T Stean; N Upton; S E Clarke; A M Brown; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 3.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

4.  Biodistribution and radiation dosimetry of the serotonin 5-HT₆ ligand [¹¹C]GSK215083 determined from human whole-body PET.

Authors:  Robert A Comley; Cristian Salinas; Romina Mizrahi; Irina Vitcu; Alvina Ng; William Hallett; Nicholas Keat; Alan A Wilson; Eugenii A Rabiner; Marc Laruelle; Sylvain Houle
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

5.  5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons.

Authors:  Matthew Brodsky; Adam J Lesiak; Alex Croicu; Nathalie Cohenca; Jane M Sullivan; John F Neumaier
Journal:  Brain Res       Date:  2017-01-10       Impact factor: 3.252

6.  Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study.

Authors:  Donatella Marazziti; Stefano Baroni; Andrea Pirone; Gino Giannaccini; Laura Betti; Lara Schmid; Elena Vatteroni; Lionella Palego; Franco Borsini; Fabio Bordi; Ilaria Piano; Claudia Gargini; Maura Castagna; Mario Catena-Dell'osso; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2012-01-26       Impact factor: 3.996

7.  Pyrano[2,3,4-cd]indole as a Scaffold for Selective Nonbasic 5-HT6R Ligands.

Authors:  Jakub Staroń; Stefan Mordalski; Dawid Warszycki; Grzegorz Satała; Adam Hogendorf; Andrzej J Bojarski
Journal:  ACS Med Chem Lett       Date:  2017-03-27       Impact factor: 4.345

8.  5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism.

Authors:  Zoltán Doleviczényi; E Sylvester Vizi; István Gacsályi; Katalin Pallagi; Balázs Volk; László G Hársing; György Halmos; Balázs Lendvai; Tibor Zelles
Journal:  Neurochem Res       Date:  2008-07-29       Impact factor: 3.996

9.  Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Authors:  Jessica A Knight; Carol Smith; Nicole Toohey; Michael T Klein; Milt Teitler
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

10.  Sequential onset of three 5-HT receptors during the 5-hydroxytryptaminergic differentiation of the murine 1C11 cell line.

Authors:  O Kellermann; S Loric; L Maroteaux; J M Launay
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.